Ma et al. [46] reported that a specific dose of GLP induces a significant effect on diabetic nephropathy, and the mechanism underlying this effect may be through inhibiting the activation of NF-κB/NLRP3 inflammatory bodies, reducing the inflammatory response, and improving renal function, thus restoring the biochemical indicators of diabetes in the blood and urine of mice with nephropathy. Here, NLRP3 is linked to diabetic kidney disease.